1. Sakakibara, S. Experiences with congenital anomalies of the heart in Japan.J. Thorac. Cardiovasc. Surg. 68,189-195 (1974).
2. Kitada M, Uheda K, Nakagawa T, et al. Follow-up study into early adulthood of patients with congenital heart diseases. Jpn. Circ. J. 51, 1409-1414 (1987).
3. Suzuki Y, Ishizawa L·, ranaka S, et al. Surgical treatment of large ventricular septal defect with pulmonary hypertension in the first 24 months of life. Ann. Thorac. Surg. 22, 228-234 (1976).
4. Kirby RR, Robison EJ, Schulz J, et al.A new pediatric volume ventilator. Anesth. Analg. 50, 533-537 (1971).
5. Olley PM, Coceani F, Bodach EVA. E-type prostaglandins: A new emergency therapy for certain cyanotic congenital heart malformations. Circulation 53, 728-731(1976).
6. Ohara T, Ogata H, Fujiyama J-I, et al. Effects of prostaglandin El infusion in the pre-operative management of critical congenital heart disease. TohokuJ. Exp. Med. 146, 237-249 (1985).
7. Satomi G, Takao A. Systematic diagnostic method of two-dimensional echocardiography in congenital heart disease. Heart Vessels 1,101-113 (1985).
8. Warnes CA, Liberthson R, Danielson GK, et al. Task force 1:the changing profile of congenital heart disease in adult life. J. Am. Coll. Cardiol.37, 1170-1175 (2001).
9. Wren C, O,Sullivan JJ. Survival with congenital heart disease and need for follow up in adult life. Heart85, 438-443 (2001).
10. Marelli AJ, Mackie AS, Ionescu-Ittu R, et al. Congenital heart disease in the general population: Changing prevalence and age distribution. Circulation 115, 163-172 (2007).
11. Moller JH, Taubert KA, Allen HD, et al. AHA Medical / Scientific statement special report cardiovascular health and disease in children : Current Status. Circulation 89, 8-10 (1994).
12. Shiina Y, royoda T, Kawasoe Y, et al. Prevalence of adult patients with congenital heart disease in Japan. Int. J. Cardiol. 146, 13-16 (2011).
13. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax26, 240- 248 (1971).
14. D’Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: Contemporary techniques have improved long-term outcomes. Circulation 116 (11 Suppl), 1157-164 (2007).
15. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA / ACC guideline for the management of adults with congenital heart disease data supplements table of contents. J. Am. Coll. Cardiol.73,1-249 (2019).
16. 日本循環器学会.循環器疾患診療実態調査報告書(2019年度実施・公表). http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2018web.pdf
17. De Rita F, Crossland D, Griselli M, et al. Management of the failing Fontan. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu.18, 2-6 (2015).
18. Pundi K, Pundi KN, Kamath PS, et al. Liver disease in patients after the Fontan operation. Am. J. Cardiol. 117, 456-460 (2016).
19. Lee D, Levin A, Kiess M, et al. Chronic kidney damage in the adult Fontan population. Int. J· Cardiol. 257, 62-66 (2018).
20. Byrne RD, Weingarten AJ, Clark DE, et al. More than the heart: Hepatic, renal, and cardiac dysfunction in adult Fontan patients. Congenit. Heart Dis.14, 765-771(2019).
21. Balushi A Al, Mackie AS. Training / practice contemporary issues in cardiology practice protein-losing enteropathy following Fontan palliation. Can J CardS,1857-1860 (2019).
22. Ohuchi H, Miyamoto Y, Yamamoto M, et al. High prevalence of abnormal glucose metabolism in young adult patients with complex congenital heart disease. Am. Heart J. 158, 30-39 (2009).
23. Ohuchi H, Yasuda K, Ono S, et al. Low fasting plasma glucose level predicts morbidity and mortality in symptomatic adults with congenital heart disease. Int. J. Cardiol. 174, 306-312 (2014).
24. Gewillig M. The Fontan circulation. Heart839-846 (2005).
25. Mori M, Aguirre AJ, Elder RW, et al. Beyond a broken heart: Circulatory dysfunction in the failing Fontan. Pediatr. Cardiol.35, 569-579 (2014).
26. Seipelt RG, Franke A, Vazquez-Jimenez JF, et al. Thromboembolic complications after fontan procedures: Comparison of different therapeutic approaches. Ann. Thorac. Surg. 74, 556-562 (2002).
27. Khairy P, Fernandes SM, Mayer JE, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 117, 85-92 (2008).
28. Jacobs, M. L, Pourmoghadam, K. K. Thromboembolism and the role of anticoagulation in the Fontan patient. Pediatr. Cardiol.28, 457-464 (2007).
29. Monagle P, Cochrane A, Roberts R, et al.A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J. Am. Coll. Cardiol.58, 645-651(2011).
30. Monagle P, Karl TR. Thromboembolic problems after the fontan operation. Pediatr.しard. Surg. Annu. 5, 36-47 (2002).
31. Faircloth JM, Miner KM, Alsaied T, et al. Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. J. Thromb. Thrombolysis44, 38-47 (2017).
32. Marrone C, Galasso G, Piccolo R, et al. Antiplatelet versus anticoagulation therapy after extracardiac conduit fontan: A systematic review and meta analysis. Pediatr. Cardiol.32, 32-39 (2011).
33. Potter BJ, Leong-Sit P, Fernandes SM, et al. Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation. Int· J. Cardiol. 168, 3940-3943 (2013).
34. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J. Am. Coll. Cardiol.74,104-132 (2019).
35. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 37, 2893-2962 (2016).
36. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. 361, 1139-1151(2009).
37. Giugliano RP, Ruff しi?, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369, 2093-2104 (2013).
38. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
39. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891(2011).
40. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149, 315-352. (2016).
41. Khairy P, van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease. Can. J.しardiol.30, el-e63 (2014).
42. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 131,263-272 (2010).
43. Pisters R, Lane DA, Nieuwlaat R, et al.A novel user-friendly score (HAS- BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 13^, 1093-1100 (2010).
44. Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool:A standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J. Thromb. Haemost. 8, 2063-2065 (2010).
45. Attard C, Huang J, Monagle P, Ignjatovic V. Pathophysiology of thrombosis and anticoagulation post Fontan surgery. Thromb. Res. 172, 204-213 (2018).
46. Yang H, Veldtman GR, Bouma BJ, et al. Non-Vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: Are they safe. Open Hear. 6,1-5 (2019).
47. Georgekutty J, Kazerouninia A, Wang YF, et al. Novel oral anticoagulant use in adult Fontan patients: A single center experience. Congenit. Heart Dis.13, 541-547 (2018).
48. McCrindle BW, Manlhiot C, Cochrane A, et al. Factors associated with thrombotic complications after the fontan procedure: A secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the fontan procedure. J. Am. Coll. Cardiol.61,346-353 (2013).
49. Firdouse M, Agarwal A, Chan AK, Mondal T. Thrombosis and thromboembolic complications in fontan patients: A literature review. Clin. Appl. Thromb. 20, 484-492 (2014).
50. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. 369, 1406-1415 (2013).
51. Liu X, Johnson M, Mardekian J, et al. Apixaban reduces hospitalizations in patients with venous thromboembolism: An analysis of the apixaban for the initial management of pulmonary embolism and deep-vein thrombosis as first-line therapy (AMPLIFY) trial. J. Am. Heart Assoc. 4,1-8 (2015).
52. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N. Engl· J. Med. 368, 699-708 (2013).
53. Tomkiewicz-Pajak L, Hoffman P, Trojnarska O, et al. Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. J. Thorac. Cardiovasc. Surg.147,1284-j.290 (2014).
54. Rathgeber SL, Guttman OR, Lee AF, et al. Fontan-associated liver disease: Spectrum of disease in children and adolescents. J. Am. Heart Assoc. 9,(l):e012529. (2020).
55. Masuda K, Ishizu T, Niwa K, et al. Increased risk of thromboembolic events in adult congenital heart disease patients with atrial tachyarrhythmias. Int. J. Cardiol. 234, 69-75 (2017).
56. Pundi KN, Pundi K, Johnson JN, et al. Contraception practices and pregnancy outcome in patients after Fontan operation. Congenit. Heart Dis.11,63-70 (2016).
57. Kilic d, iuksel B, Doganay M, et al. The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement. Contraception 80,152-157 (2009).